
- ACME ABC
Trial Status
Open
Cancer Type
Biliary tract cancer
If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
Protocol Title
Australian Comprehensive Molecular Evaluation of Advanced Biliary Cancer (ACME ABC) Trial
Purpose of the Study
Biliary cancer (BC) remains a rare but important cause of cancer related mortality. Surgical resection is the only potentially curative treatment; however, the majority of patients present with advanced biliary cancer (ABC) are not surgical candidates. Instead, these patients are offered palliative chemotherapy. The median survival of patients with ABC is between 1-2 years.
The ACME ABC study will review the feasibility and potential benefit of instituting routine comprehensive molecular profiling of patients with ABC using either fresh, frozen or archival tissue obtained at the time of routine diagnostic tests.
Contact email
Detailed information available
More detailed information to come
Study Chairs
Dr Daniel Croagh
Dr Owen McKay
funding
2021 AGITG-Pancare Cholangiocarcinoma Idea Generation Workshop Grant
Participating Centres
Trial Status
Open
Cancer Type
Biliary tract cancer
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.